Group Environmental Report for 2006 Published
August 30 2006 - 6:13AM
PR Newswire (US)
BERLIN, Germany, August 30 /PRNewswire-FirstCall/ -- Schering (FSE:
SCH, NYSE: SHR) has been successfully upholding its commitment to
safety, health care and environmental protection. This, together
with its social commitment, is documented in the company's current
Group Environmental Report, published every two years. For example,
emissions at the company's pharmaceutical production sites were
further decreased thanks to the use of the latest technology and
the replacement of older equipment. The implementation of a
modernized central wastewater treatment plant at Schering's largest
production site in Bergkamen led to a considerable reduction in the
amount of wastewater. In addition, energy saving measures were
implemented at many sites as well as individual photovoltaic
projects to lower the amount of CO2 emissions. It was also possible
to reduce the number of occupational accidents throughout the
Group. "Society and the environment need corporate responsibility.
We believe a balance of economic, environmental and social
interests is a key to long-term success", said Dr. Karin Dorrepaal,
Member of the Executive Board at Schering AG responsible for
Industrial Operations & Environment, as well as Corporate
Procurement. "Our research activities and innovative abilities are
of both corporate and social significance. We help in recognizing
diseases, to cure them and so prolong life." As part of its comment
to better health care, alongside further measures to supply
medicine, Schering made some 35 million cycles of oral
contraceptives available as well as two million contraceptive
injections in the last year alone. In this way, the company
supports family planning projects in developing countries. Further
information A printed version of the Group Environmental Report,
published in German and English, is available free of charge from
Schering AG, Corporate Communication, Ms. Kerstin Buscher, (Tel.:
+49-30-468-121-22, Fax: +49-30-468-166-46, e-mail: ). The Report is
also available on the Internet - together with a Spanish version -
at http://www.schering.de/ in the Media Center, under the rubric
Company Reports. Schering AG is a research-based pharmaceutical
company. Its activities are focused on four business areas:
Gynecology&Andrology, Oncology, Diagnostic Imaging as well as
Specialized Therapeutics for disabling diseases. As a global player
with innovative products Schering AG aims for leading positions in
specialized markets worldwide. With in-house R&D and supported
by an excellent global network of external partners, Schering AG is
securing a promising product pipeline. Using new ideas, Schering AG
aims to make a recognized contribution to medical progress and
strives to improve the quality of life: making medicine work Your
contacts at Corporate Communication Media Relations: Oliver Renner
, T: +49-30-468-124-31, Gabriele Liebmann-El Badry, T:
+49-30-468-156-25, Further information at: www.schering.de Certain
statements in this press release that are neither reported
financial results nor other historical information are
forward-looking statements, including but not limited to,
statements that are predictions of or indicate future events,
trends, plans or objectives. Undue reliance should not be placed on
such statements because, by their nature, they are subject to known
and unknown risks and uncertainties and can be affected by other
factors that could cause actual results and Schering AG's plans and
objectives to differ materially from those expressed or implied in
the forward-looking statements. Certain factors that may cause such
differences are discussed in our Form 20-F and Form 6-K reports
filed with the U.S. Securities and Exchange Commission. Schering AG
undertakes no obligation to update publicly or revise any of these
forward-looking statements, whether to reflect new information or
future events or circumstances or otherwise. DATASOURCE: Schering
AG CONTACT: Media Relations: Oliver Renner , T: +49-30-468-124-31,
, Gabriele Liebmann-El Badry, T: +49-30-468-156-25,
Copyright